Company: GANX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001558370-25-005829
Chunk: 30

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 30
---
 Ernst & Young AG. All services and fees described below were pre-approved by the Audit Committee.

| ​             
 ​             | ​ 
 ​ | ​                 
 Fiscal Year Ended 
 ​                 |       ​ 
    2024 | ​ | ​ 
 ​ |       ​ 
    2023 |
|:--------------|:--|:------------------|--------:|:--|:--|--------:|
| Audit Fees(1) | ​ | $                 | 606,012 | ​ | $ | 698,474 |
| Tax Fees(2)   | ​ | ​                 |   8,144 | ​ |   |  39,245 |
| Total Fees    | ​ | $                 | 614,156 | ​ | $ | 737,719 |

| (1) | “Audit Fees” represent the aggregate fees and expenses for professional services rendered in relation to the audit of our consolidated financial statements on Form 10-K and the review of our quarterly condensed consolidated financial statements on Form 10-Q, and the statutory audit fees of our Swiss subsidiary. It also includes professional services rendered in connection with issuance of consents included in registration statements and issuance of comfort letters. |

| (2) | “Tax Fees” consist of fees and expenses for professional services mainly related to tax compliance and tax advice. |

Pre-Approval Policies and Procedures The Audit Committee has adopted procedures for the pre-approval of audit and non-audit services rendered by our independent registered public accounting firm, Ernst & Young AG. Pre-approval may also be given as part of the Audit Committee’s approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit Committee’s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting. THE BOARD RECOMMENDS A VOTE “FOR” PROPOSAL 2.

20

PROPOSAL 3 APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE OUR AUTHORIZED SHARES OF COMMON STOCK FROM 50,000,000 TO 100,000,000 Our Board has approved, subject to stockholder approval, an Amendment to our Certificate to increase our authorized shares of common stock from 50,000,000 to 100,000,000. The increase in our authorized shares of common